Lotte Biologics builds 360,000 liters antibody drug production facility by 2030
폴 리
hoondork1977@alphabiz.co.kr | 2023-06-21 01:13:45
[Alpha Biz=(Chicago) Reporter Paul Lee] Lotte BioLogics said on the 20th that it has signed a four-way MOU (business agreement) with Lotte Holdings, Incheon Metropolitan City and Incheon Free Economic Zone Authority to quickly build a local biopharmaceutical production facility.
Under this agreement, Lotte BioLogics, Lotte Holdings, Incheon Metropolitan City and Incheon Free Economic Zone Authority will establish a strategic cooperative relationship to expedite the construction of Lotte BioLogics' domestic mega plant by the end of this year and revitalize the Songdo bio cluster.
Lotte BioLogics plans to produce three mega plants and a total of 360,000 liters of antibody drugs in Korea by 2030. 120,000 liters of antibody drugs can be produced per plant, and small cultivators and finished drug facilities to produce clinical materials will also be added.
It will also create a Bio-Venture Initiative" that will provide facilities for bio-venture companies at the local mega-plant complex and set the stage for cooperation in technology development."
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 4Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 5Korean Air and LCC Affiliates Enter Emergency Management as Fuel Costs Surge Amid Middle East Conflict
- 6Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures